Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Endoxifen’s Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens

28 Jan 2013

Abstract excerpt

Endoxifen, a cytochrome P450 mediated tamoxifen metabolite, is being developed as a drug for the treatment of estrogen receptor (ER) positive breast cancer. Endoxifen is known to be a potent anti-estrogen and its mechanisms of action are still being elucidated. Here, we demonstrate that endoxifen-mediated recruitment of ERα to known target genes differs from that of 4-hydroxy-tamoxifen (4HT) and ICI-182,780...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen and related hormone effects
Share to Inflammatory mediators and NSAID effects
Share to Pharmacogenetics and Drug Metabolism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23382923
DOI: 10.1371/journal.pone.0054613

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Endoxifen’s Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-EstrogensPMID 23382923Read ↗

Endoxifen, a Secondary Metabolite of Tamoxifen, and 4-OH-Tamoxifen Induce Similar Changes in Global Gene Expression Patterns in MCF-7 Breast Cancer CellsSemantic proximity Read ↗

A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients.Semantic proximity Read ↗

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.Semantic proximity Read ↗

Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifenSemantic proximity Read ↗

CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.Semantic proximity Read ↗

Clinical and biomarker predictors of side effects from tamoxifen.Semantic proximity Read ↗

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.Semantic proximity Read ↗

CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.Semantic proximity Read ↗

Fast and Adequate Liquid Chromatography-Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring.Semantic proximity Read ↗

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.Semantic proximity Read ↗

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.Semantic proximity Read ↗

Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.